Search result from the Trials Tracker
Phase 1/2 safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of VX-121
- Trials Tracker ID
- TT001981
- Age range
- 18 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Adults with cystic fibrosis often have low iron levels (iron deficiency). This is partly due to poor absorption of iron from the gut, and partly to the trapping of iron within cells of the immune system during periods of infection. Unfortunately, iron tablets are often ineffective in this setting, and may cause significant side effects in patients with cystic fibrosis. In other patient groups, intravenous iron is used routinely to correct iron deficiency. In these patients it has been shown to be safe, and to improve energy levels, exercise tolerance, cognitive function and quality of life, even in the absence...
- Trials Tracker ID
- TT001976
- Age range
- 18 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Nutritional-GI
Search result from the Trials Tracker
This trial has been archived
TRIAL RESULTS LINK: https://erj.ersjournals.com/content/56/suppl_64/1275 There are many oscillatory PEP devices on the market to use for chest physiotherapy, with strong evidence that they are effective treatments in clearing the lungs. However, they don’t provide the user feedback to confirm that they are using the correct technique or indicate when each blow or treatment session has been completed. As a result this can lead parents to have a lack of confidence in whether their child is completing the physiotherapy session correctly or completely.A father of a CF patient has developed a device alongside the CF team at Cambridge University Hospital called...
- Trials Tracker ID
- TT001971
- Age range
- Between 8 and 16 years
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
Airway clearance treatments (ACTs) and physical activity can mitigate the progression of CF lung disease, but these routine physiotherapy treatments are burdensome and adherence is low. Traditional research methods have failed to produce credible evidence to guide practice, partly because ‘blinding’ isn’t possible and patient preference can confound results. We have worked with engineers and designers to develop an electronically chipped sensor (Fizzyo sensor) which mounts onto standard widely used airway clearance devices. This sensor monitors breathing during routine airway clearance. Additionally wearable activity trackers can monitor physical activity. We can now facilitate automatic transmission of ACT and physical activity...
- Trials Tracker ID
- TT001966
- Age range
- Between 6 and 16 years
- Length of participation
- 14 months
- Trial status
- Closed with results
- Therapeutic approach
- Behavioural
Search result from the Trials Tracker
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
- Trials Tracker ID
- TT001956
- Age range
- 12 years and older
- Trial status
- Recruitment complete
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Vertex made the decision to terminate study VX17-659-105 when the entire VX-659 programme was halted in favour of a more effective programme in the same patient population.
- Trials Tracker ID
- TT001951
- Age range
- 12 years and older
- Trial status
- Study discontinued early
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Kaftrio treatment was generally safe and effective for people with cystic fibrosis ages 12+ with Phe508del-minimal function genotypes for whom previous CFTR modulator treatments were not effective. These results support Kaftrio as a treatment for people with these gene variants.
- Trials Tracker ID
- TT001941
- Age range
- 12 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
The study is a randomized, double-blind, placebo-controlled, study that will be conducted at multiple centers in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation.
- Trials Tracker ID
- TT001936
- Age range
- 18 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This study tests the effects of an experimental drug PC945 in people with cystic fibrosis whose lungs are infected by the fungus Aspergillus fumigatus. PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will continue to be treated with their usual cystic fibrosis treatment and will also receive PC945. The amount of fungus in the patients' phlegm will be measured over the course of the study. The study will take place at multiple sites in...
Four people were recruited onto the study and one person withdrew when the study was temporarily paused. The study was then terminated early as a result of the COVID-19 pandemic.
- Trials Tracker ID
- TT001926
- Age range
- 18 years and older
- Trial status
- Study discontinued early
- Therapeutic approach
- Anti-Infective
